RETGENTX
Overcoming the challenge of large gene transfer for the therapy of inherited retinal diseases
| Coordinatore | FONDAZIONE TELETHON
Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie. |
| Nazionalità Coordinatore | Italy [IT] |
| Totale costo | 1˙500˙000 € |
| EC contributo | 1˙500˙000 € |
| Programma | FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | ERC-2011-StG_20101109 |
| Funding Scheme | ERC-SG |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-01-01 - 2016-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
FONDAZIONE TELETHON
Organization address
address: VIA VARESE 16/B contact info |
IT (ROMA) | hostInstitution | 1˙500˙000.00 |
| 2 |
FONDAZIONE TELETHON
Organization address
address: VIA VARESE 16/B contact info |
IT (ROMA) | hostInstitution | 1˙500˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Inherited retinal diseases (IRDs) cause blindness in over 200,000 individuals in Europe. The majority are due to mutations in genes expressed in photoreceptors (PR) in the retina. We have recently demonstrated the safety and efficacy of gene therapy for IRDs in patients with Leber congenital amaurosis (LCA). One of the major limitations to extend this clinical success to other blinding conditions is that many are caused by mutations in genes with large coding sequences that exceed the cargo capacity of the most efficient gene transfer vector for PR, the adeno-associated virus (AAV). Conversely, vectors for large gene delivery like lentiviral (LV) or high-capacity adenoviral (HC-Ad) vectors have poor PR tropism. This project aims at overcoming the challenge of large gene delivery to the retina. We propose to either expand AAV cargo capacity or to identify/modify LV and HD-Ad vectors with improved PR transduction ability. We plan to expand AAV cargo capacity by either producing AAV vectors from single plasmid containing large genes or by generating 2-split AAV vectors each containing one of 2 halves of a large gene which is reconstituted upon AAV intermolecular concatemerization in the nucleus of target cells. In parallel, we will screen a series of existing LV pseudotypes and Ad serotypes for their ability to transduce PR. Alternatively, we propose to modify the Ad capsid or LV envelope using epitopes identified by in vivo biopanning that bind to PR and. We will compare the efficiency of the three vector platforms to transduce murine and porcine PR. The platform with highest PR transduction efficiency will then be used to correct the retinal phenotype of murine models of common severe IRDs due to mutations in large genes. Overcoming the challenge of large gene transfer will allow to cure photoreceptor-specific diseases which are currently untreatable and will provide important therapeutic tools for those diseases targeting tissues other than the retina.'